Breaking News: Large Study Shows Measuring Medication Risk with MedWise® Can Help Reduce Premature Death
Click to learn what these findings mean for medication safety and practice

Jacques Turgeon, BPharm, PhD

Jacques Turgeon, BPharm, PhD
Chief Scientific Officer

Jacques Turgeon, BPharm, PhD is the Chief Scientific Officer at TRHC. Dr. Turgeon obtained his BPharm and PhD from Laval University, Quebec City, Canada. He then completed a fellowship training in clinical pharmacology at Vanderbilt University. Dr. Turgeon is recognized internationally for his excellence in research and pharmacy education. During his academic career, he has received more than $70 million in research awards, authored more than 187 peer-reviewed articles and mentored nearly 70 students. His research interests focus on studying factors responsible for the intersubject variability in drug response, and he is renowned for his expertise on the cytochrome P450 system, the role of pharmacogenetics in cardiovascular drug actions, drug-induced Long QT syndrome and the development of clinical decision support systems and medication risk scores.

Dr. Turgeon has held numerous leadership roles, such as Research Director of the Quebec Heart Institute; Dean of the School of Pharmacy and Vice-Rector of Research at the University of Montreal; Director of the University of Montreal Hospital Research Centre; Chief Executive Officer of the University of Montreal University Hospital. More recently he served as the Associate Dean, College of Pharmacy, University of Florida. Dr. Turgeon is Professor Emeritus from University of Montreal, a fellow of the Canadian Academy of Health Sciences and an international fellow of the Académie Nationale de Médecine in France.